Avanza Fonder Ab Autolus Therapeutics PLC Transaction History
Avanza Fonder Ab
- $3.86 Trillion
- Q3 2025
A detailed history of Avanza Fonder Ab transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Avanza Fonder Ab holds 53,522 shares of AUTL stock, worth $74,395. This represents 0.0% of its overall portfolio holdings.
Number of Shares
53,522
Previous 53,522
-0.0%
Holding current value
$74,395
Previous $122 Million
28.51%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AUTL
# of Institutions
104Shares Held
150MCall Options Held
24.6KPut Options Held
41.9K-
Mak Capital One LLC New York, NY26MShares$36.2 Million6.54% of portfolio
-
Blackstone Inc New York, NY20.5MShares$28.5 Million0.15% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$23.1 Million97.83% of portfolio
-
Armistice Capital, LLC New York, NY15.6MShares$21.7 Million0.39% of portfolio
-
Tfg Asset Management Gp LTD Grand Cayman, E99.5MShares$13.2 Million3.44% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $126M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...